Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Net Income	144,067	317,017	230,059	376,005	44,241
Depreciation & Amortization	728,002	664,400	583,151	559,671	583,649
Share-Based Compensation	70,871	60,672	43,374	37,663	29,122
Other Operating Activities	-226,596	-64,933	266,521	37,592	12,740
Operating Cash Flow	716,344	977,156	1,123,105	1,010,931	669,752
Operating Cash Flow Growth	-26.69%	-13.00%	11.10%	50.94%	103.89%
Capital Expenditures	-166,814	-139,695	-121,437	-64,753	-114,504
Acquisitions	19,959	7,958	-21,476	530,388	456,656
Change in Investments	-18,854	15,665	11,981	62,395	43,233
Other Investing Activities	-298,153	-491,030	-67,193	-134,500	-93,266
Investing Cash Flow	-463,862	-607,102	-198,125	393,530	292,119
Dividends Paid	-287,188	-279,416	-283,665	-283,357	-282,582
Share Issuance / Repurchase	-2,326	-26,929	-77,531	-2,141	-3,737
Debt Issued / Paid	1,513	-285,071	-600,477	-660,504	-586,090
Other Financing Activities	-66,415	-117,732	-108,592	-142,352	-132,804
Financing Cash Flow	-354,416	-709,148	-1,070,265	-1,088,354	-1,005,213
Exchange Rate Effect	26,204	22,929	28,758	12,501	-21,766
Net Cash Flow	-101,934	-339,094	-145,285	316,107	-43,342
Free Cash Flow	549,530	837,461	1,001,668	946,178	555,248
Free Cash Flow Growth	-34.38%	-16.39%	5.86%	70.41%	84.15%
Free Cash Flow Margin	12.89%	20.79%	28.07%	29.59%	16.87%
Free Cash Flow Per Share	175.13	270.09	320.36	303.70	177.40

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).